



MARKET RELEASE

9 April 2018

MGC PHARMACEUTICALS LTD

TRADING HALT

The securities of MGC Pharmaceuticals Ltd (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Wednesday, 11 April 2018 or when the announcement is released to the market.

Security Code: MXC

Anjuli Sinniah
Senior Adviser, Listings Compliance (Perth)

9 April 2018

Australian Securities Exchange
Level 40, Central Park
152-158 St Georges Tce
Perth WA 6000

Via email: tradinghaltspert@asx.com.au

Dear Sir/Madam

The Directors of MGC Pharmaceuticals Ltd (the “Company”) request that the Company’s securities be placed in a voluntary trading halt immediately in accordance with ASX Listing Rule 17.1, pending the release of an announcement by the Company regarding a material transaction in relation to the award of a full medical cannabis production and cultivation facility contract in the European Union (EU), and a related capital raising.

The Company requests that the trading halt end on the earlier of the commencement of normal trading on Wednesday 11 April 2018, or when the detailed announcement regarding the full details of the transaction is released to the market.

The Company is not aware of any reason why the trading halt should not be granted, nor of any other information necessary to inform the market about the trading halt, and the Company confirms that the request for a trading halt is material.

Yours faithfully



Brett Mitchell
Executive Chairman